In Brief: Psivida, Compumedics, Avantogen
Wednesday, 22 June, 2005
Psivida (ASX:PSD) has released the full results of its Phase IIa trial of BrachySil in inoperable primary liver cancer patients, showing that the product is safe and effective in prompting tumour regression.
Compumedics (ASX:CMP) has promoted Dr Curtis Ponton to vice president and chief scientist for the Compumedics Neuroscan business group following the departure of Dr Stephen Sands.
Paul Hopper, who resigned as CEO and managing director of Australian Cancer Technologies (ASX:ACU) -- now known as Avantogen -- in February, has been appointed chairman of US based biotech Innovate Oncology (OTC:IOVO), a company founded by Bioaccelerate Holdings (OTC:BACLE). Innovate Oncology owns the North American rights, with Avantogen, to RP-101, a pancreatic cancer drug currently in Phase II clinical studies.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
